Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 11/20 | 0.62 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.59 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.59 |
| ▸ | ITGAL | P20701 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879639 | 0.81 | KDM4E (0.64) | PYGLHPGDALDH1A1KDM4E | |
| SCHEMBL19508587 | 0.80 | HSD17B3 (0.54) | PYGLHPGDALDH1A1APP | |
| SCHEMBL13879643 | 0.79 | ITGB2 (0.68) | PYGLITGB2ICAM1ITGALALDH1A1 | |
| SCHEMBL6499764 | 0.79 | ITGB2 (0.52) | PYGLITGB2ICAM1ITGALHPGD | |
| SCHEMBL6499766 | 0.79 | ITGB2 (0.52) | PYGLITGB2ICAM1ITGALHPGD | |
| SCHEMBL27557325 | 0.78 | ITGB2 (0.90) | PYGLITGB2ICAM1ITGAL | |
| SCHEMBL10980220 | 0.77 | MAPT (0.67) | PYGLITGB2ICAM1ITGAL | |
| SCHEMBL10980223 | 0.77 | MAPT (0.67) | PYGLITGB2ICAM1ITGAL | |
| SCHEMBL13879637 | 0.76 | NPC1 (0.54) | PYGLITGB2ICAM1ITGALALDH1A1 | |
| SCHEMBL18385865 | 0.75 | APP (0.80) | PYGLITGB2ICAM1ITGALAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | PYGL 5/4885ITGB2 4487/4885ICAM1 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.